LB Pharmaceuticals Inc (LBRX)
NGM · Healthcare · Biotechnology
$44.63
-3.50%
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
Market Cap
$1.44B
Shares Outstanding
32.3M
Exchange
NGM
Currency
USD
About LB Pharmaceuticals Inc
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (5.2M) | (13.9M) | (22.1M) | (53.9M) |
| Net Income | (3.6M) | (11.5M) | (19.1M) | (51.6M) |
| Diluted EPS | $-0.61 | $-0.45 | $-0.67 | $-1.71 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (2.8M) | (11.4M) | (64.8M) | (30.4M) |
| Net Income | (14.3M) | (6.3M) | (63.1M) | (25.2M) |
| Diluted EPS | $-4.05 | $-1.77 | $-17.82 | $-3.13 |